South Africa seeks local production of Gilead's HIV prevention drug

Core Viewpoint - South Africa is initiating efforts to produce Gilead Sciences' long-acting HIV prevention drug, lenacapavir, locally to enhance access in the region most affected by the HIV pandemic [1][2]. Group 1: Local Production Initiative - The South African government is collaborating with international partners to identify local manufacturers capable of producing lenacapavir safely and affordably [1][2]. - Gilead has previously granted six voluntary licenses to generic manufacturers in countries like India, Egypt, and Pakistan, but no South African companies were included in those agreements [1][2]. - A potential license for a South African company would be the seventh deal, which could significantly improve access to the drug [1][2]. Group 2: HIV Pandemic Context - Sub-Saharan Africa remains the epicenter of the HIV pandemic, with South Africa having approximately 8 million people living with HIV, representing about one in five adults [1][2]. - Local production of lenacapavir is seen as a critical step in addressing the region's health needs, as reliance on imported medicines has been a challenge [1][2]. Group 3: Access Challenges - There have been historical delays in the availability of HIV drugs in low- and middle-income countries compared to wealthier nations [1][2]. - Lenacapavir is currently available in some African countries through initiatives supported by The Global Fund and the U.S. government, but demand is expected to exceed supply until local production begins [1][2]. - The inclusion of a South African manufacturer could also help expand access to middle-income countries like Brazil, which have been excluded from previous agreements [1][2].